戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 entations (peptic ulcer, gastric cancer, and atrophic gastritis).
2 otential concern in patients with autoimmune atrophic gastritis.
3  circumvent the pH alteration resulting from atrophic gastritis.
4 redominantly in tissues showing gastritis or atrophic gastritis.
5  strains isolated from patients with chronic atrophic gastritis.
6 sually occurs in stomachs containing chronic atrophic gastritis.
7 important role in the development of chronic atrophic gastritis.
8 s associated with the development of chronic atrophic gastritis.
9 re not significantly associated with chronic atrophic gastritis.
10 te to tumorigenesis in patients with chronic atrophic gastritis.
11 amin B12 remains intact in older people with atrophic gastritis.
12  of hypergastrinemia associated with chronic atrophic gastritis.
13 secretors of acid, most had serum markers of atrophic gastritis.
14 ramework for the diagnosis and management of atrophic gastritis.
15 y almost invariably implies the diagnosis of atrophic gastritis.
16 ally discuss the diagnosis and management of atrophic gastritis.
17  guidance on the diagnosis and management of atrophic gastritis, a common preneoplastic condition of
18 c superficial gastritis that may progress to atrophic gastritis, a premalignant process.
19 otic transgenic mouse model of human chronic atrophic gastritis, a preneoplastic condition.
20 Barret's esophagus (2.6% vs. 1.3%; P=0.006), atrophic gastritis according to endoscopist's judgment (
21 tors for EE, whereas H. pylori infection and atrophic gastritis act as protective factors.
22 as an efficient model for the development of atrophic gastritis after infection and to determine the
23                                              Atrophic gastritis (AG) and gastric intestinal metaplasi
24             Gastric premalignant conditions, atrophic gastritis (AG) and intestinal metaplasia (IM) a
25                                              Atrophic gastritis (AG) and use of proton pump inhibitor
26 biopsy specimens from 74 patients, including atrophic gastritis (AG) cases without aspirin use (contr
27 ase-control study, the main risk factors for atrophic gastritis (AG) were comprehensively analyzed in
28 s are associated with autoimmune metaplastic atrophic gastritis (AMAG).
29 ly related to a higher prevalence of chronic atrophic gastritis and a lower prevalence of smoking.
30 e associated with hypergastrinaemia, chronic atrophic gastritis and achlorhydria.
31 NS-GAS and B6 wild-type mice had both severe atrophic gastritis and corpus dysplasia, while GAS-KO mi
32 d characteristictly found in assciation with atrophic gastritis and gastric cancer consistent with Bh
33                        The high incidence of atrophic gastritis and gastric cancer suggest the phylog
34 ze the human stomach and have been linked to atrophic gastritis and gastric carcinoma.
35 ting gastrin levels, and develop spontaneous atrophic gastritis and gastrointestinal intraepithelial
36                      The presence of chronic atrophic gastritis and Helicobacter pylori infection was
37 min malabsorption, which usually arises from atrophic gastritis and hypochlorhydria but other mechani
38    Decreased Bcl-2 gene expression signified atrophic gastritis and IM in presence of cancer, as well
39                             Overall PPVs for atrophic gastritis and intestinal metaplasia were 12.4%
40                       Index lesions included atrophic gastritis and intestinal metaplasia.
41 hanges in the gastric mucosa, beginning with atrophic gastritis and leading in some patients to pepti
42  the investigation of a patient with chronic atrophic gastritis and multiple large gastric carcinoid
43   To examine the association between chronic atrophic gastritis and other gastric cancer risk factors
44 how helminth coinfection may protect against atrophic gastritis and T helper type 1 responses.
45                      Individuals with severe atrophic gastritis and/or multifocal or incomplete GIM a
46    We evaluated 19 superficial gastritis, 18 atrophic gastritis, and 18 intestinal metaplasia from ca
47 duces acute gastritis, peptic ulcer disease, atrophic gastritis, and gastric adenocarcinoma.
48  range of pathology, including peptic ulcer, atrophic gastritis, and gastric cancer.
49 tis, has been associated with a high risk of atrophic gastritis, and is considered a gastric tumor pr
50                     Individuals with chronic atrophic gastritis are considered to be at increased ris
51 ACTICE ADVICE 4: When endoscopic features of atrophic gastritis are present, providers should assess
52 ype I gastric carcinoids in individuals with atrophic gastritis are typically indolent, especially if
53 there is heterogeneity in the definitions of atrophic gastritis, autoimmune gastritis, pernicious ane
54 tric histopathology implies the diagnosis of atrophic gastritis because intestinal metaplasia occurs
55  adenocarcinoma rests on the assumption that atrophic gastritis can be correctly identified and repro
56                                      Chronic atrophic gastritis can lead to gastric metaplasia and in
57 er pylori infection in patients with chronic atrophic gastritis, can cause metaplasia, characterized
58 gastrointestinal), impaired iron absorption (atrophic gastritis, celiac disease, bariatric surgical p
59  on host biology-the transition from chronic atrophic gastritis (ChAG) to gastric adenocarcinoma-and
60 er, a subset of individuals develops chronic atrophic gastritis (ChAG), a condition characterized in
61                                      Chronic atrophic gastritis (ChAG), a Helicobacter pylori-associa
62 hat develop an antecedent condition, chronic atrophic gastritis (ChAG).
63 ; 2) gastric IM adjacent to a GU but with no atrophic gastritis changes; 3) patients receiving H. pyl
64 d be considered in individuals with advanced atrophic gastritis, defined based on anatomic extent and
65 tion of the stomach, with a primary focus on atrophic gastritis due to chronic Helicobacter pylori in
66 sia (SPEM) develops in patients with chronic atrophic gastritis due to infection with Helicobacter py
67  with loss of acid-secreting parietal cells (atrophic gastritis), expansion of foveolar cells, and re
68 hical biopsies to confirm corpus-predominant atrophic gastritis for risk stratification and to rule o
69 rent study tests the hypothesis that chronic atrophic gastritis from hypochlorhydria in the gastrin-d
70 ed with reduced pepsin output independent of atrophic gastritis, H. pylori infection, and smoking.
71 redominant (HR 1.284, 95% CI 1.04-1.57), and atrophic gastritis (HR 4, 95% CI 3.07-5.21) were indepen
72                                          The atrophic gastritis in the infected wild-type mice, parti
73 n the elderly, owing to a high prevalence of atrophic gastritis in this age group.
74  included, of which 37 were cases of chronic atrophic gastritis, intestinal metaplasia, or dysplasia.
75 d vitamin B-12 deficiencies in patients with atrophic gastritis irrespective of etiology, especially
76 ce Advice Statements BEST PRACTICE ADVICE 1: Atrophic gastritis is defined as the loss of gastric gla
77 opic surveillance interval for patients with atrophic gastritis is not well-defined and should be dec
78 ive once preneoplastic lesions of multifocal atrophic gastritis (MAG) and intestinal metaplasia (IM)
79 postulated to initiate a progression through atrophic gastritis, metaplasia and dysplasia to cancer,
80 ces gastric cancer risk in patients with non-atrophic gastritis (NAG), and is ineffective once preneo
81 alt diet groups developed moderate to marked atrophic gastritis of the corpus in response to H. pylor
82 psinogen ratios of less than 2.9, indicating atrophic gastritis, only 2 (5%) of 44 consistent or inte
83 gastric cancer (GC) and adjacent mucosa with atrophic gastritis or intestinal metaplasia (AG/IM GC+),
84 stinal metaplasia (AG/IM GC+), as well as in atrophic gastritis or intestinal metaplasia mucosa of pa
85 . pylori infection (OR 0.56 [0.48-0.66]) and atrophic gastritis (OR 0.51 [0.31-0.86]) are protective
86 cy of documenting the extent and severity of atrophic gastritis, particularly if marked atrophy is pr
87 gnificantly increases the risk of developing atrophic gastritis, peptic ulcer disease, and gastric ad
88  topic, and the terms "gastric atrophy" and "atrophic gastritis" remain imprecisely defined and, ther
89 s related to the diagnosis and management of atrophic gastritis remains very limited in the United St
90                                Nevertheless, atrophic gastritis represents an important stage with di
91                                              Atrophic gastritis results in a low acid-pepsin secretio
92              Furthermore, hypochlorhydria in atrophic gastritis results in bacterial overgrowth of th
93 BEST PRACTICE ADVICE 6: All individuals with atrophic gastritis should be assessed for H pylori infec
94 Regardless of the etiology, the diagnosis of atrophic gastritis should be confirmed by histopathology
95 unexplained iron or vitamin B-12 deficiency, atrophic gastritis should be considered in the different
96 alues in ruling out the infection and corpus atrophic gastritis, thereby potentially reducing the nee
97                               By focusing on atrophic gastritis, this Clinical Practice Update is int
98                                              Atrophic gastritis was defined as a ratio of serum pepsi
99 ssion, the significant predictors of chronic atrophic gastritis were age over 50 years, H. pylori inf
100 uld recognize typical endoscopic features of atrophic gastritis, which include pale appearance of gas
101 resulted in chronic diffuse lymphofollicular atrophic gastritis with areas of mucosal dysplasia in th
102 stologic risk-stratification parameters when atrophic gastritis with or without metaplasia is diagnos

 
Page Top